Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
| Status: | Archived |
|---|---|
| Conditions: | Blood Cancer, Lymphoma, Orthopedic, Hematology |
| Therapuetic Areas: | Hematology, Oncology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | May 2003 |
| End Date: | December 2013 |
A Phase I/II Study of Vaccination Against Minor Histocompatibility Antigens HA1 or HA2 After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
This is a clinical research study designed to evaluate whether the administration of a
vaccine to patients after transplant consisting of a minor histocompatibility antigen (mHag
peptide) mixed with G-CSF (a drug intended to stimulate the immune system) can stimulate
increased graft versus leukemia (GVL) responses without causing graft-versus-host disease
(GVHD).
We found this trial at
1
site
University of Chicago One of the world's premier academic and research institutions, the University of...
Click here to add this to my saved trials
